Orphan Café, 27 juni 2013
Prof. dr. Gertjan van Ommen (Leiden University Medical Centre)
Bekijk alle presentaties van de Orphan Cafés op:
http://www.orphancafe.nl/presentaties/
Orphan Café, 27 juni 2013
Prof. dr. Gertjan van Ommen (Leiden University Medical Centre)
Bekijk alle presentaties van de Orphan Cafés op:
http://www.orphancafe.nl/presentaties/
IWO Meeting 1 November 2023 - Stopping with Denosumab and Romosozumab, basic mechanisms and clinical aspects door Prof. dr. S. Ferrari, Geneva, Switzerland. (Engelstalige lezing)
1) DXA scanning is a reliable and low-radiation method to measure bone mineral density (BMD) at the lumbar spine, hip, and wrist to diagnose osteoporosis.
2) DXA can also detect vertebral fractures (VFA) and measure whole body composition, abdominal fat, and aortic calcification.
3) Interpretation of DXA results requires attention to potential variability between devices, accurate placement of regions of interest, and use of appropriate reference data since BMD can be under or overestimated in certain patients.
This document summarizes osteonecrosis of the jaw (ONJ) associated with antiresorptive agents. It defines ONJ and stages its severity. It discusses the pathogenesis of ONJ and risk factors like underlying disease, treatment duration, and dental procedures. Cancer patients on intravenous bisphosphonates have the highest ONJ risk of 1-8% due to higher drug doses and worse oral/general health. Management involves conservative measures like mouthwashes for early stages and surgery with antibiotics for later stages. Discontinuing antiresorptives may help healing but risks fractures. Teriparatide may help healing in some cases but its use in cancer is uncertain. More research is needed on preventing and treating established ON
This systematic review analyzed 895 cases of tumor-induced osteomalacia (TIO) from case reports. TIO is caused by tumors that produce excess fibroblast growth factor 23 (FGF23), which causes hypophosphatemia and osteomalacia. The review found that TIO mostly affects adults aged 40-60 years old, with long diagnostic delays of several years on average. The tumors were located variably but most commonly in the lower limbs or head and neck region. Higher FGF23 levels correlated with larger tumor size. Patients experienced significant bone fragility and fracture rates as high as 60% due to long-term hypophosphatemia. Early tumor detection and removal are important to improve outcomes for
This document discusses real-world evidence on denosumab for osteoporosis treatment and fracture prevention. It summarizes several studies, including one that found denosumab reduced fracture risk by 38% compared to placebo in over 25,000 postmenopausal women. Another study showed good long-term persistence with denosumab therapy in over 800 patients. Additional studies observed that zoledronic acid can prevent bone loss following denosumab discontinuation, and bisphosphonate treatment after denosumab provides protection against new vertebral fractures.
IWO Meeting 16 November 2022 - ASBMR young talent: Silvia Storoni (Amsterdam): Prevalence and Hospital Admissions in Patients With Osteogenesis Imperfecta in The Netherlands: A Nationwide Registry Study
The document appears to be a presentation on highlights from the ASBMR 2021 conference in San Diego. It discusses several topics that were covered at the conference, including fracture risk assessment, the effects of various osteoporosis treatments on bone mineral density, safety issues like osteonecrosis of the jaw and atypical femoral fractures, the role of vitamin D, and applications of artificial intelligence. The entire document is copyrighted by Prof. Dr. Joop van den Bergh.
This document discusses guidelines for medication to prevent fractures in patients using glucocorticoids. It notes that glucocorticoids significantly increase the risk of vertebral and non-vertebral fractures. While effective anti-osteoporosis drugs are available, many glucocorticoid-treated patients remain untreated. The document reviews new guidelines that simplify treatment criteria to improve implementation and outlines recommendations for when to start bone-sparing medications based on patient factors and glucocorticoid dose and duration. The goal is to optimize fracture prevention in glucocorticoid-treated patients.
This document discusses what actions should be taken when a vertebral fracture is discovered incidentally. It notes that vertebral fractures are very common fractures, especially in older individuals, and are often asymptomatic. Having a vertebral fracture significantly increases one's risk for future fractures both in the short and long term. If a vertebral fracture is found incidentally, such as on a CT scan, further investigation is warranted including assessing bone mineral density and checking for underlying bone diseases. Treatment options should also be considered, especially if the individual has low bone density in addition to the vertebral fracture, as this combination confers the highest risk. New automated detection algorithms aim to help identify vertebral fractures on scans to ensure appropriate follow up for individuals.
This document summarizes a cost-effectiveness model of Fracture Liaison Services (FLS) care in the Netherlands. The model found that FLS care would be highly cost-effective, with a cost of €9,076 per quality-adjusted life year gained. Total 5-year costs with FLS would be only 1.7% higher than current costs but would prevent fractures and improve health outcomes. The model can help decision-makers prioritize secondary fracture prevention and allow local payers and FLS to predict costs and benefits of implementation.
This document discusses recommendations from the European Calcified Tissue Society (ECTS) regarding treatment after stopping denosumab therapy. It summarizes findings from ECTS papers in 2017 and 2021 on risks of rebound vertebral fractures when discontinuing denosumab. The ECTS recommends pretreatment or post-treatment with bisphosphonates to prevent bone mineral density loss and fractures after stopping denosumab, especially for those on long-term denosumab therapy of over 2.5 years. New Dutch guidelines advise treating with denosumab for 3 years, then reevaluating fracture risk before extending treatment another 3 years up to a maximum of 10 years, and ensuring adequate bisphosphonate treatment after stopping to prevent
IWO bijeenkomst - 14 april - Prof. Dr. J.P. van den Bergh
IWO Bijeenkomst - 11 april - D. van de Laarschot
1. Atypische femurfracturen (AFF)
Is preventie mogelijk?
Denise van de Laarschot
ANIOS, PhD student Endocrinologie, Botcentrum
Erasmus MC, Rotterdam
2. (potentiële) belangenverstrengeling Geen
Voor bijeenkomst mogelijk relevante
relaties met bedrijven
Geen
Sponsoring of onderzoeksgeld
Honorarium of andere (financiële)
vergoeding
Aandeelhouder
Andere relatie, namelijk …
Disclosures
3. Antiresorptiva: gevaarlijke medicijnen?
• Bisfosfonaten
• Denosumab
Severely suppressed bone turnover: a potential complication of alendronate therapy. Odvina. 2005. JCEM.
Osteonecrose van de kaak
Atypische femurfractuur
(AFF)
4. AFF zeldzaam, maar grote impact!
50% daling in gebruik orale bisfosfonaten tussen 2008-
2012
Adapted from: Trends in media reports, oral BP prescriptions and hip fractures 1996-2012. Jha et al. JBMR 2015.
5. Fractuurrisico met en zonder bisfosfonaten
0
500
1000
1500
2000
2500
3000
3500
4000
4500Incidentieper100.000
persoon-jaren
Bisfosfonaat
Onbehandeld
Adapted from: Adler et al. JBMR 2016.
Absolute AFF risico
zeer laag!
6. Fractuurrisico met en zonder bisfosfonaten
0
500
1000
1500
2000
2500
3000
3500
4000
4500Incidentieper100.000
persoon-jaren
Bisfosfonaat
Onbehandeld
Adapted from: Adler et al. JBMR 2016.
AFF risico stijgt bij
langdurig
bisfosfonaten
14. Risicofactoren AFF
• (Langdurig) bisfosfonaten/denosumab
• Veel comorbiditeit/comedicatie:
– Corticosteroïden
• Toegenomen kromming femur
– Aziatische afkomst
Shane et al. Second report of ASBMR Task force. JBMR 2014.
15. Genetische factoren
Erfelijkheid aannemelijk vanwege optreden van AFF in:
- families
- individuen zonder bisfosfonaatgebruik
- individuen met erfelijke botziekte
van de Laarschot et al. Genetic risk factors for AFFs: a systematic review. JBMR PLUS. Nov 2017
16. AFF in 18-jarige met osteoporose bij PLS3 mutatie
van de Laarschot, Zillikens. Case report in Bone Oct. 2016.
18. Verlengde femurscan met DXA
• Incomplete AFF zichtbaar op heup-DXA1
• Verlengde femurscan met DXA kan AFF detecteren2
Reguliere heup-DXA Verlengde femurscan
1McKiernan. Atypical femoral diaphyseal fractures documented by serial DXA. J. Clin Densitom. 2013
2McKenna et al. Incomplete atypical femoral fractures: assessing the diagnostic utility of DXA by extended femur length. J Clin Densit 2013.
19. Methoden
• Verlengde femurscan beiderzijds bij routine DXA
• In alle patiënten met antiresorptiva gebruik
• Juni 2014 – Augustus 2016
• Beoordeling op “beaking” (visueel)
• Beaking = lokale corticale verdikking lateraal
• Bevestiging AFF op X-femur
24. Resultaten
Totaal aantal ptn
n=282
Beaking
n=12 (4.3%)
X-femur beschikbaar
n=5
4 incomplete AFFs
n=4
Calcificatie weke
delen
n=1
Aanvullende X-femur
n=5
6 incomplete AFFs
n=5 (1.8%)
Geen X-femur
n=2
25. Samenvattend
• 10 incomplete AFFs in 9 patiënten (3.2%)
• Alle bekende gevallen van incomplete AFF zichtbaar
• 6 nieuwe AFFs in 5 patiënten
• 1 patiënt preventieve OK; staken antiresorptiva
26. Samenvattend
• 10 incomplete AFFs in 9 patiënten (3.2%)
• Alle bekende gevallen van incomplete AFF zichtbaar
• 6 nieuwe AFFs in 5 patiënten
• 1 patiënt preventieve OK; staken antiresorptiva
Slechts 2 van de 9 patiënten met incomplete AFF
gaven spontaan pijnklachten aan
31. AFF: ook mediale localisatie?
van de Laarschot et al. “Atypical” atypical femur fractures and use of bisphosphonates.
Sep 2016. Clinical Cases of Mineral and Bone Metabolism.
33. Screenen met DXA: voordelen
• Positief voorspellende waarde “beaking” = 83.3%
• Klinisch relevant: behandelconsequentie!
• DXA al onderdeel van patiëntenzorg
• Ook screening bij patiënten zonder pijn
• Zeer geringe stralingsbelasting
• Slechts ~1 minuut extra scantijd
34. Screenen met DXA: beperkingen
• Vals negatieve femurscans niet uit te sluiten
• Minimale verandering misschien niet zichtbaar
– Verschil met software?
• Screenen kan leiden tot onnodige X-foto’s
• Overschatting van prevalentie AFF (5.2% in studie)
Afbeeldingen: GE Lunar AFF software.
35. Screenen met DXA: conclusies
• De verlengde femurscan is een klinisch relevante
screeningmethode in patiënten die antiresorptiva
gebruiken
• Vooral aanbevolen bij pijn of hoog-risico patiënten
• Echter onbekend hoe (snel) AFF zich ontwikkelt
36. Voorkómen is beter dan genezen
• Voorspellers van AFF
– Kliniek: patiëntkenmerken
– Genetica: exome sequencing
– Anatomie: heupgeometrie*
– Botkwaliteit: TBS*
* van de Laarschot et al. Trabecular bone score and Hip structural analysis in patients with AFF. Maart 2018.
Journal of Clinical Densitometry.
37. Monogenetische botziekten geassocieerd met AFF
Monogenetic
bone disorder
Genes associated
with disorder
Gender Age (yrs) Bilateral
AFF
n
BP exposure
n
Disorder diagnosed
following AFF
n
Hypophosphatasia ALPL 4 F 50-55 4 1 4
XLH PHEX 1 M 27 0 0 0
Pycnodysostosis CTSK
3 M
4 F
23-55 3 0 2
Osteopetrosis
TCIRG1,CLCN7,
OSTM1,PLEKHM1,
SNZ10,TNFS11,
TNFRSF11A,CA11
4 F 21-56 2 0 1
OPPG LRP5 1 M 38 0 0 1
OI
COL1A1/1A2, CRTAP,
LEPRE1, PPIB,
SERPINH1, FKBP10,
PLOD2, SP7
4 F
1 M
11-75 2 5 0
X-linked
Osteoporosis
PLS3 1 M 18 0 1 0
AFF= atypical femur fracture, F=female, M=male, BP=bisphosphonate, XLH=X-linked hypophosphataemia, OPPG=osteoporosis
pseudoglioma syndrome, OI=osteogenesis imperfect
van de Laarschot et al. Genetic risk factors for AFFs: a systematic review. JBMR PLUS. Nov 2017
38. Monogenetische botziekten geassocieerd met AFF
Monogenetic
bone disorder
Genes associated
with disorder
Gender Age (yrs) Bilateral
AFF
n
BP exposure
n
Disorder diagnosed
following AFF
n
Hypophosphatasia ALPL 4 F 50-55 4 1 4
XLH PHEX 1 M 27 0 0 0
Pycnodysostosis CTSK
3 M
4 F
23-55 3 0 2
Osteopetrosis
TCIRG1,CLCN7,
OSTM1,PLEKHM1,
SNZ10,TNFS11,
TNFRSF11A,CA11
4 F 21-56 2 0 1
OPPG LRP5 1 M 38 0 0 1
OI
COL1A1/1A2, CRTAP,
LEPRE1, PPIB,
SERPINH1, FKBP10,
PLOD2, SP7
4 F
1 M
11-75 2 5 0
X-linked
Osteoporosis
PLS3 1 M 18 0 1 0
AFF= atypical femur fracture, F=female, M=male, BP=bisphosphonate, XLH=X-linked hypophosphataemia, OPPG=osteoporosis
pseudoglioma syndrome, OI=osteogenesis imperfect
Mineralization defect
Defect in bone remodeling
Defect in collagen synthesis
Defect in osteocyte function
van de Laarschot et al. Genetic risk factors for AFFs: a systematic review. JBMR PLUS. Nov 2017
39. Monogenetische botziekten geassocieerd met AFF
Monogenetic
bone disorder
Genes associated
with disorder
Gender Age (yrs) Bilateral
AFF
n
BP exposure
n
Disorder diagnosed
following AFF
n
Hypophosphatasia ALPL 4 F 50-55 4 1 4
XLH PHEX 1 M 27 0 0 0
Pycnodysostosis CTSK
3 M
4 F
23-55 3 0 2
Osteopetrosis
TCIRG1,CLCN7,
OSTM1,PLEKHM1,
SNZ10,TNFS11,
TNFRSF11A,CA11
4 F 21-56 2 0 1
OPPG LRP5 1 M 38 0 0 1
OI
COL1A1/1A2, CRTAP,
LEPRE1, PPIB,
SERPINH1, FKBP10,
PLOD2, SP7
4 F
1 M
11-75 2 5 0
X-linked
Osteoporosis
PLS3 1 M 18 0 1 0
AFF= atypical femur fracture, F=female, M=male, BP=bisphosphonate, XLH=X-linked hypophosphataemia, OPPG=osteoporosis
pseudoglioma syndrome, OI=osteogenesis imperfect
16 van 23 patiënten zonder
bisfosfonaatgebruik
van de Laarschot et al. Genetic risk factors for AFFs: a systematic review. JBMR PLUS. Nov 2017
40. Monogenetische botziekten geassocieerd met AFF
Monogenetic
bone disorder
Genes associated
with disorder
Gender Age (yrs) Bilateral
AFF
n
BP exposure
n
Disorder diagnosed
following AFF
n
Hypophosphatasia ALPL 4 F 50-55 4 1 4
XLH PHEX 1 M 27 0 0 0
Pycnodysostosis CTSK
3 M
4 F
23-55 3 0 2
Osteopetrosis
TCIRG1,CLCN7,
OSTM1,PLEKHM1,
SNZ10,TNFS11,
TNFRSF11A,CA11
4 F 21-56 2 0 1
OPPG LRP5 1 M 38 0 0 1
OI
COL1A1/1A2, CRTAP,
LEPRE1, PPIB,
SERPINH1, FKBP10,
PLOD2, SP7
4 F
1 M
11-75 2 5 0
X-linked
Osteoporosis
PLS3 1 M 18 0 1 0
AFF= atypical femoral fracture, F=female, M=male, BP=bisphosphonate, XLH=X-linked hypophosphataemia, OPPG=osteoporosis
pseudoglioma syndrome, OI=osteogenesis imperfect
8 van de 23 patiënten kregen
diagnose erfelijke botziekte pas
na de AFF
van de Laarschot et al. Genetic risk factors for AFFs: a systematic review. JBMR PLUS. Nov 2017
41. AFF-studie
– 50 patiënten in NL geïncludeerd
– Internationaal consortium
Aanmelden proefpersoon voor AFF-studie:
d.vandelaarschot@erasmusmc.nl
Denise van de Laarschot, ANIOS, PhD student
42. Veel dank aan:
Dr. Carola Zillikens, Els van Zaanen, Sandra Smits,
internist-endocrinoloog röntgenlaborant researchverpleegkundige
https://www.erasmusmc.nl/botcentrum
/